AGXT and Insulin resistance: Compelling evidence has shown that blocking SPT activity with myriocin (an SPT-specific inhibitor) decreases ceramide, SM, and glucosylceramide (GluCer) levels and attenuates MAFLD and insulin resistance (19, 20, 21, 22).